Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug
Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he’s confirmed to lead the Department of Health and Human Services? And
Related Articles
Kaiser Permanente, Tufts launch food-is-medicine network
The new Food is Medicine National Network of Excellence aims to expand and improve nutrition- and diet-based healthcare practices.
‘It’s tectonic:’ U.S. foreign aid freeze deals a blow to research around the globe
Dismantling of USAID could disrupt many clinical trials and wipe away U.S. “soft power” in developing countries, scientists warn
Diagnostic accuracy of gasdermin D as a biomarker for necrotizing enterocolitis: a single-center diagnostic test study
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal condition mainly affecting premature infants, and gasdermin D (GSDMD) has emerged as a molecule of interest due to…
Robotic extended total extraperitoneal transversus abdominus release for traumatic flank and abdominal intercostal hernias
Hernia – Traumatic abdominal intercostal/flank hernias present a perplexing challenge for surgeons seeking to repair them. There has been a paucity of studies describing robotic…
One Month Whole Food Plant-Based Nutrition Educational Program Lowers LDL, A1C, and Decreases Inflammatory Markers
Lifestyle-related chronic disease increases in the United States have led to the need for innovative programs targeting dietary choices. Based on growing evidence supporting whole…
UC Davis Researchers Achieve Total Synthesis of Ibogaine
Ibogaine — a psychoactive plant derivative — has attracted attention for its anti-addictive and anti-depressant properties. But ibogaine is a finite resource, extracted from plants…
Obese and healthy
Body weight and body mass index alone are not enough to predict whether someone will develop a metabolic disease. A new atlas of cells in…
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.
